Ambroxol Reneval, 7.5 mg/ml 4 ml 15 pcs

Studies have shown that the active ingredient of the drug, ambroxol, increases secretion in the respiratory tract. It increases production of pulmonary surfactant and stimulates ciliary activity. These effects result in increased mucus flow and transport (mucociliary clearance). Strengthening of mucociliary clearance improves sputum discharge and facilitates coughing.

In patients with chronic obstructive pulmonary disease long-term therapy with this drug (for at least 2 months) led to a significant reduction in exacerbations. There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.

Indications

Acute and chronic diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty in sputum discharge, bronchiectasis.

Pharmacological effect

Studies have shown that the active ingredient of the drug, ambroxol, increases secretion in the respiratory tract. It enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough.

In patients with chronic obstructive pulmonary disease, long-term drug therapy (for at least 2 months) led to a significant reduction in the number of exacerbations. There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.

Active ingredient

Ambroxol

Composition

Active ingredient:
Ambroxol hydrochloride – 7,500 mg
Excipients:
sodium chloride – 6.220 mg
sodium hydrogen phosphate dihydrate – 4.350 mg
citric acid monohydrate – 2,000 mg
benzalkonium chloride – 0.225 mg
purified water – up to 1,000 ml

Contraindications

Hypersensitivity to ambroxol or other components of the drug, pregnancy (first trimester), lactation period.

Side Effects

Gastrointestinal disorders:
Often (1.0 – 10.0%) – nausea, decreased sensitivity in the oral cavity or pharynx;
Uncommon (0.1 – 1.0%) – dyspepsia, vomiting, diarrhea, abdominal pain, dry mouth;
Rarely (0.01 – 0.1%) – dry throat.

With caution

Ambroxol should not be taken simultaneously with antitussive drugs that impede the removal of sputum.
The solution contains the preservative benzalkonium chloride, which, when inhaled, can cause bronchospasm in sensitive patients with increased respiratory tract reactivity.

Interaction

No clinically significant, undesirable interactions with other drugs have been reported.
When used simultaneously with amoxicillin, cefuroxime, erythromycin, ambroxol increases their concentration in bronchial secretions.

Overdose

No specific symptoms of overdose have been described in humans.

There have been reports of accidental overdose and/or medical error resulting in symptoms of known side effects of the drug: nausea, dyspepsia, vomiting, diarrhea, abdominal pain. In this case, there may be a need for symptomatic therapy.

Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug, symptomatic therapy.

Recommendations for use

Application of the solution internally (1 ml=25 drops):
adults and children over 12 years old: 4 ml (=100 drops) 3 times a day;
children from 6 to 12 years old: 2 ml (=50 drops) 2-3 times a day;
children from 2 to 6 years: 1 ml (=25 drops) 3 times a day;
children under 2 years old: 1 ml (=25 drops) 2 times a day.
Drops can be diluted in water, tea, juice or milk. The solution can be used regardless of meals.

Application of the solution in the form of inhalations:
adults and children over 6 years old: 1-2 inhalations of 2-3 ml of solution per day;
children under 6 years of age: 1-2 inhalations of 2 ml of solution per day.
The drug solution can be used using any modern equipment for inhalation (except steam inhalers). To achieve optimal hydration during inhalation, the drug is mixed with a solvent (sodium chloride 0.9%) in a 1:1 ratio.

Since during inhalation therapy a deep breath can provoke a cough, inhalations should be carried out in normal breathing mode. Before inhalation, it is recommended to warm the inhalation solution to body temperature.

Manufacturer

Update of PFC JSC, Russia